The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
The Performance of AFP, AFP-3, DCP as Biomarkers for Detection of Hepatocellular Carcinoma (HCC): A Phase 3 Biomarker Study in the United States
Open accessAbstract
Background: AFP, AFP L-3 and DCP in combination or in GALAD were tested for HCC surveillance in retrospective cohort and case-control studies. However, there is a paucity of prospective data and no phase 3 biomarker studies from North American populations. Methods: We conducted a prospective-specimen collection, retrospective-blinded-evaluation (PRoBE) cohort study in patients with cirrhosis enrolled in a 6-monthly surveillance with liver imaging and AFP. Blood samples were prospectively collected every 6 months and analyzed in a retrospective blinded fashion. True positive rate (TPR) and false positive rate (FPR) for any or early HCC were calculated within 6, 12 and 24 months of HCC diagnosis based on published thresholds for biomarkers individually, in combination and in GALAD and HES scores. We calculated the area under the receiver operating curve (AUROC) and estimated TPR based on an optimal threshold at a fixed FPR of 10%. Results: The analysis was conducted in a cohort of 534 patients; 50 developed HCC (68% early) and 484 controls with negative imaging. GALAD had the highest TPR (63.6, 73.8, 71.4% for all HCC, and 53.8, 63.3, 61.8 % for early HCC within 6, 12 and 24 months, respectively) but FPR of 21.5–22.9%. However, there were no differences in AUROC among GALAD, HES, AFP-3 or DCP. At a fixed 10% FPR, TPR for GALAD dropped (42.4, 45.2, 46.9%) and was not different from HES (36.4, 40.5, 40.8%) or AFP-3 alone (39.4, 45.2, 44.9%). Conclusions: In a prospective cohort phase 3 biomarker study, GALAD was associated with a considerable improvement in sensitivity for HCC detection but an increase in false positive results. GALAD performance was modest and not different from AFP-3 alone or HES.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phases of Biomarker Development for Early Detection of Cancer
Pepe, M. S., Etzioni, R., Feng, Z., Potter, J. D., Thompson, M. L., Thornquist, M., Winget, M., & Yasui, Y. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.14.1054 · Cited by 1,686
Tayob, N., Richardson, P., White, D. L., Yu, X., Davila, J. A., Kanwal, F., Feng, Z., & El-Serag, H. B. (2018) · BMC Medical Research Methodology · doi:10.1186/s12874-017-0458-6 · Cited by 217
Self-citation
Cited by
Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
Hwang, S. Y., Danpanichkul, P., Agopian, V., Mehta, N., Parikh, N. D., Abou-Alfa, G. K., Singal, A. G., & Yang, J. D. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0824 · Cited by 306
Opportunities to address gaps in early detection and improve outcomes of liver cancer
McMahon, B., Cohen, C., Brown Jr, R. S., El-Serag, H., Ioannou, G. N., Lok, A. S., Roberts, L. R., Singal, A. G., & Block, T. (2023) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkad034 · Cited by 44
Self-citationMao, R., & Li, J. (2024) · BMC Medical Genomics · doi:10.1186/s12920-024-02008-0 · Cited by 5
Metadata
- Authors
- Tayob, N., Kanwal, F., Alsarraj, A., Hernaez, R., & El-Serag, H. B.
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2023-02
- Volume
- 21
- Issue
- 2
- Pages
- 415-423.e4
- ISSN
- 1542-3565 (ISSN-L)
- OpenAlex
- W4210499162
- Cited by
- 228
- References
- 2
- FWCI
- 23.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.